The emergence of COVID-19 almost five years ago forced us all to face the realities of containing and mitigating a highly transmissible, deadly pandemic.
The field of biologics is vast and growing, with tremendous potential to improve patients’ lives and public health.
Assurances of safety and effectiveness play an important role in instilling confidence among healthcare providers in any new class of medicines. Those assurances include knowing that mandatory public standards for quality and naming have been adhered to in the manufacture of medicines. Find out what this means for top selling biologics in the U.S.
Over the past three decades, generic medicines have significantly increased patient access to quality treatment, while lowering healthcare costs in the United States. Learn how a new class of prescription drugs knows as biosimilars, offers the same hope of increased access and reduced costs.
The American drug supply is among the safest in the world, with many protections for consumers and patients. However, a pending proposal in Congress would remove key protections for all biologic drugs—crucial and lifesaving medicines we take like insulin, human growth hormones, and blood thinners. Learn more.
Legislation being considered by Congress will remove the requirement that all biologic medicines – drugs such as insulin, vaccines, cancer treatments and other therapies made using living matter – comply with public quality standards of the U.S. Pharmacopeia (USP). This same legislation would also apply to biosimilars. As a result, public confidence in biologics and biosimilars as well as patient safety would be at risk. Learn more.
Show 11 More